Sun Pharma rose 2.20 per cent to close at Rs 1,484.55 after reports surfaced that the company may extend its tender offer for all outstanding shares of Taro, until November 7. As per the earlier proposal, the tender offer was to expire on October 3.
The tender offer is priced at $7.75 per share and in the eventuality of the offer being fully subscribed, Sun’s equity interest in the Israeli pharma company will increase from 36 per cent to 48 per cent. Sun hit an intraday high of Rs 1,495 and a low of Rs 1,432, with trading volumes of 8,912.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app